News
Paxlovid shelf life extended in Japan
Japanese regulatory authorities have approved a shelf-life extension for Pfizer’s oral COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) from 18 months to 24 months
The shelf-life of the drug was originally 12 months upon its special approval in February 2022. It was extended to 18 months in September last year based on stability testing data, and thanks to additional data, it was further extended to 24 months, effective February 10.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.